RT Journal Article
SR Electronic
T1 Advances in treatment of chronic hepatitis C: ‘Pegylated’ interferons
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 155
OP 159
VO 69
IS 2
A1 Sharieff, Khavir A.
A1 Duncan, David
A1 Younossi, Zobair
YR 2002
UL http://www.ccjm.org/content/69/2/155.abstract
AB New regimens consisting of pegylated interferons plus ribavirin may produce a sustained virologic response in more than 50% of cases of chronic hepatitis C. In contrast, the combination of standard interferon alfa and ribavirin, which was the standard of care until recently, produced a sustained virologic response in 35% to 40% of cases. As the efficacy of newer regimens improves, additional steps to adequately manage their side effects and maximize adherence may become crucial.